Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $23.50, but opened at $22.69. Chugai Pharmaceutical shares last traded at $23.0950, with a volume of 19,079 shares trading hands.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy”.

Chugai Pharmaceutical Stock Performance

The firm has a market cap of $73.88 billion, a price-to-earnings ratio of 24.94 and a beta of 0.58. The stock’s 50 day simple moving average is $25.94 and its 200-day simple moving average is $27.28.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings data on Friday, April 24th. The company reported $0.22 earnings per share for the quarter. The firm had revenue of $2.05 billion for the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%. On average, analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.